Generic name for novel Hsp90 inhibitor approved

11 February 2008

US drug firms Infinity Pharmaceuticals and MedImmune say that the US Adopted Names (USAN) Council, in consultation with the World Health Organization's International Nonproprietary Names Expert Committee, has approved the use of the non-proprietary or generic name retaspimycin for the companies' lead heat shock protein 90 (Hsp90) inhibitor, -504.

Retaspimycin HCl is currently being evaluated in clinical trials for the potential treatment of a variety of solid tumor cancers, including gastrointestinal stromal tumors, non-small cell lung cancer and hormone resistant prostate cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight